ZA985669B - New formulation - Google Patents

New formulation

Info

Publication number
ZA985669B
ZA985669B ZA985669A ZA985669A ZA985669B ZA 985669 B ZA985669 B ZA 985669B ZA 985669 A ZA985669 A ZA 985669A ZA 985669 A ZA985669 A ZA 985669A ZA 985669 B ZA985669 B ZA 985669B
Authority
ZA
South Africa
Prior art keywords
new formulation
formulation
new
Prior art date
Application number
ZA985669A
Other languages
English (en)
Inventor
Joanne Broadhead
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA985669(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of ZA985669B publication Critical patent/ZA985669B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA985669A 1997-07-11 1998-06-29 New formulation ZA985669B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation

Publications (1)

Publication Number Publication Date
ZA985669B true ZA985669B (en) 1999-01-11

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985669A ZA985669B (en) 1997-07-11 1998-06-29 New formulation

Country Status (36)

Country Link
US (1) US6130208A (sv)
EP (1) EP1000079B1 (sv)
JP (1) JP4950380B2 (sv)
KR (1) KR100786654B1 (sv)
CN (2) CN1864696A (sv)
AR (1) AR013157A1 (sv)
AT (1) ATE340801T1 (sv)
AU (1) AU8362598A (sv)
BR (1) BR9810703A (sv)
CA (1) CA2295628C (sv)
CY (1) CY1105805T1 (sv)
CZ (1) CZ298110B6 (sv)
DE (1) DE69836023T2 (sv)
DK (1) DK1000079T3 (sv)
EE (1) EE04119B1 (sv)
ES (1) ES2273425T3 (sv)
HK (1) HK1026429A1 (sv)
HU (1) HU226489B1 (sv)
ID (1) ID24716A (sv)
IL (2) IL133868A0 (sv)
IS (1) IS2439B (sv)
MY (1) MY116421A (sv)
NO (1) NO329918B1 (sv)
NZ (1) NZ502073A (sv)
PL (1) PL192768B1 (sv)
PT (1) PT1000079E (sv)
RU (1) RU2216330C2 (sv)
SA (1) SA98190328B1 (sv)
SE (1) SE9702680D0 (sv)
SI (1) SI1000079T1 (sv)
SK (1) SK285766B6 (sv)
TR (1) TR200000006T2 (sv)
TW (1) TW585764B (sv)
UA (1) UA65576C2 (sv)
WO (1) WO1999002542A1 (sv)
ZA (1) ZA985669B (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879567B2 (en) * 2004-10-05 2011-02-01 Asahi Kasei Pharma Corporation Method for stabilizing coenzyme and composition therefor
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8729095B2 (en) 2009-08-28 2014-05-20 Daiichi Sankyo Company, Limited 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases
PL2498731T3 (pl) 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
FI2648701T3 (fi) * 2010-12-10 2023-06-12 Sigmapharm Laboratories Llc Hyvin stabiileja adefovirdipivoksiilin koostumuksia
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
DK2744424T3 (en) 2011-08-17 2018-01-22 Samuel Shiber Adaptively rotating catheter to open clogged vessels in the body
BR112015022070B1 (pt) 2013-03-09 2022-01-18 Chiesi Farmaceutici S.P.A. Uso de cangrelor
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
CA2971868C (en) 2015-01-14 2023-04-04 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
US11260071B2 (en) 2017-06-23 2022-03-01 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
TW202016088A (zh) 2018-06-19 2020-05-01 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (sv) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
TW326045B (en) * 1993-02-10 1998-02-01 Astra Pharma Prod N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation.
NZ270077A (en) * 1993-12-14 1996-04-26 Lilly Co Eli Aqueous complexes of benzothiophenes and cyclodextrins
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
EP0833667A4 (en) * 1995-06-07 2001-11-21 Univ California STABILIZATION OF POLYNUCLEOTIDE COMPLEXES
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Also Published As

Publication number Publication date
PT1000079E (pt) 2006-12-29
JP2001509512A (ja) 2001-07-24
SK183699A3 (en) 2000-07-11
EP1000079A1 (en) 2000-05-17
IL133868A (en) 2010-05-17
BR9810703A (pt) 2000-08-08
SI1000079T1 (sl) 2007-08-31
PL192768B1 (pl) 2006-12-29
PL337970A1 (en) 2000-09-11
NO20000123L (no) 2000-03-03
CY1105805T1 (el) 2011-02-02
EE04119B1 (et) 2003-08-15
CN1263533A (zh) 2000-08-16
CZ298110B6 (cs) 2007-06-27
WO1999002542A1 (en) 1999-01-21
ID24716A (id) 2000-08-03
CN1864696A (zh) 2006-11-22
KR20010021647A (ko) 2001-03-15
CA2295628A1 (en) 1999-01-21
NO20000123D0 (no) 2000-01-10
EE200000022A (et) 2000-10-16
IS2439B (is) 2008-11-15
RU2216330C2 (ru) 2003-11-20
SK285766B6 (sk) 2007-07-06
TR200000006T2 (tr) 2000-07-21
US6130208A (en) 2000-10-10
HUP0002622A3 (en) 2002-04-29
NO329918B1 (no) 2011-01-24
EP1000079B1 (en) 2006-09-27
DK1000079T3 (da) 2006-11-20
KR100786654B1 (ko) 2007-12-21
SE9702680D0 (sv) 1997-07-11
ATE340801T1 (de) 2006-10-15
HK1026429A1 (en) 2000-12-15
MY116421A (en) 2004-01-31
CZ200083A3 (cs) 2000-06-14
SA98190328B1 (ar) 2006-08-15
IL133868A0 (en) 2001-04-30
UA65576C2 (uk) 2004-04-15
IS5331A (is) 1999-12-30
NZ502073A (en) 2001-09-28
HUP0002622A2 (hu) 2001-05-28
JP4950380B2 (ja) 2012-06-13
DE69836023T2 (de) 2007-04-12
HU226489B1 (en) 2009-03-02
ES2273425T3 (es) 2007-05-01
AU8362598A (en) 1999-02-08
TW585764B (en) 2004-05-01
CA2295628C (en) 2008-07-29
AR013157A1 (es) 2000-12-13
DE69836023D1 (de) 2006-11-09

Similar Documents

Publication Publication Date Title
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
GB9715751D0 (en) Formulations
ZA9811461B (en) New formulation
GB9726916D0 (en) Nasal formulation
DE69840493D1 (en) Tionseinlage
ZA9710601B (en) Novel formulation
DE69810944D1 (en) Hydroperoxidzersetzungsverfahren
GB2323024B (en) Mopheads
ZA985669B (en) New formulation
ZA984230B (en) Carotenoid formulation
GB9724544D0 (en) Novel Formulation
ZA9810184B (en) New phenyl-alkyl-imidazoles
GB9727518D0 (en) Use
EP0968655A4 (en) SPREAD
DE59708342D1 (en) Basophilen-degranulationstest
ZA9810773B (en) Revitalisation formulation
GB9810180D0 (en) Novel formulation
GB9706957D0 (en) Formulation
DE69805998D1 (en) Photowirksame cumarinderivate
ZA976592B (en) Formulation
DE69737400D1 (en) Substituierte naphthopyrane
GB2330196B (en) Starcloth
GB9721807D0 (en) Formulation
GB9725275D0 (en) Formulation
GB9713339D0 (en) G-seat